KR930001913A - Eye Treatment - Google Patents

Eye Treatment Download PDF

Info

Publication number
KR930001913A
KR930001913A KR1019920013296A KR920013296A KR930001913A KR 930001913 A KR930001913 A KR 930001913A KR 1019920013296 A KR1019920013296 A KR 1019920013296A KR 920013296 A KR920013296 A KR 920013296A KR 930001913 A KR930001913 A KR 930001913A
Authority
KR
South Korea
Prior art keywords
inflammatory
therapeutic agent
rapamycin
weight
effective anti
Prior art date
Application number
KR1019920013296A
Other languages
Korean (ko)
Other versions
KR100216768B1 (en
Inventor
쉬리 크리쉬나 쿨카르니 프러사드
Original Assignee
원본미기재
유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 filed Critical 원본미기재
Publication of KR930001913A publication Critical patent/KR930001913A/en
Application granted granted Critical
Publication of KR100216768B1 publication Critical patent/KR100216768B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Disclosed is a method and composition for treating ocular inflammation in a mammal in need of such treatment, including administering to the mammal an anti-inflammatory amount of rapamycin. <IMAGE>

Description

안염 치료방법Eye Treatment

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 대조군과 비교하여 덱사메탄손, 시클로스포린 A 및 라파마이신으로서 처리후 방수(aqueous humor)에서 백혈구의 수준변화를 나타낸 막대 그래프이다,FIG. 1 is a bar graph showing the changes in leukocyte levels in aqueous humor after treatment with dexamethasone, cyclosporin A and rapamycin compared to control.

제2도는 대조군과 비교하여 덱사메타손, 시클로스포린 A 및 라파마이신으로서 처리후 방수에서 단백질의 수준변화를 나타낸 막대 그래프이다,FIG. 2 is a bar graph showing changes in protein levels in aqueous humor after treatment with dexamethasone, cyclosporin A and rapamycin compared to control. FIG.

제3A및 3B도는 대조군과 비교하여 덱사메타손, 시클로스포린 A및 라파마이신으로 처리한후 각각 방수에서 PGE2와 LTB4의 수준변화를 나타낸 막대 그래프이다.3A and 3B are bar graphs showing changes in PGE 2 and LTB 4 levels in aqueous humor after treatment with dexamethasone, cyclosporin A and rapamycin, respectively, compared to controls.

Claims (6)

활성성분으로서 라파마이신을 유효 항염중량으로 이루어진, 안염치료가 필요한 포유류의 안염치료제.An anti-inflammatory agent for a mammal in need of an inflammatory treatment comprising rapamycin as an active ingredient with an effective anti-inflammatory weight. 제1항에 있어서, 안염이 포도막염, 결막염, 상공막염, 공막염, 시신경염, 구후시신경염, 눈의 외과수술에 따른 안염, 및 물리적인 눈의 외상에서 유래한 안염중에서 선택되는 것이 특징인 치료제.The therapeutic agent according to claim 1, wherein the ophthalmitis is selected from uveitis, conjunctivitis, scleritis, scleritis, optic neuritis, posterior optic neuritis, ophthalmitis following surgery of the eye, and ophthalmitis derived from physical eye trauma. 제1항에 있어서, 상기 치료제의 투여경로가 경구, 비경구, 국소, 경피 및 직장투여중에서 선택되는 것이 특징인 치료제.The therapeutic agent according to claim 1, wherein the route of administration of the therapeutic agent is selected from oral, parenteral, topical, transdermal and rectal administration. 제1항에 있어서, 라파마이신의 유효 항염중량이 약0.1-50mg/kg/일인 것이 특징인 치료제.The therapeutic agent of claim 1, wherein the effective anti-inflammatory weight of rapamycin is about 0.1-50 mg / kg / day. 제4항에 있어서, 라파마이신의 유효 항염중량이 약0.01-35mg/kg/일인 것이 특징인 치료제.The therapeutic agent of claim 4, wherein the effective anti-inflammatory weight of rapamycin is about 0.01-35 mg / kg / day. 제4항에 있어서, 라파마이신의 유효 항염중량이 약0.3-25mg/kg/일인 것이 특징인 치료제.The therapeutic agent of claim 4, wherein the effective anti-inflammatory weight of rapamycin is about 0.3-25 mg / kg / day. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920013296A 1991-07-25 1992-07-24 Rapamycin as a medicament for the treatment of occular inflammation KR100216768B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73560491A 1991-07-25 1991-07-25
US7/735,604 1991-07-25
US07/735,604 1991-07-25

Publications (2)

Publication Number Publication Date
KR930001913A true KR930001913A (en) 1993-02-22
KR100216768B1 KR100216768B1 (en) 1999-09-01

Family

ID=24956475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920013296A KR100216768B1 (en) 1991-07-25 1992-07-24 Rapamycin as a medicament for the treatment of occular inflammation

Country Status (20)

Country Link
US (1) US5387589A (en)
EP (1) EP0532862B1 (en)
JP (1) JP2568962B2 (en)
KR (1) KR100216768B1 (en)
AT (1) ATE133336T1 (en)
AU (1) AU653415B2 (en)
CA (1) CA2074641C (en)
CZ (1) CZ285660B6 (en)
DE (1) DE69207847T2 (en)
DK (1) DK0532862T3 (en)
ES (1) ES2083030T3 (en)
HK (1) HK1005705A1 (en)
HU (1) HU211218B (en)
IE (1) IE922430A1 (en)
IL (1) IL102414A (en)
MX (1) MX9204381A (en)
NZ (1) NZ243679A (en)
RU (1) RU2048812C1 (en)
SK (1) SK280511B6 (en)
ZA (1) ZA924953B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990048077A (en) * 1997-12-08 1999-07-05 전원중 Manufacturing method of artificial marble molding

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0581959T3 (en) * 1991-04-26 2001-01-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for eye diseases
AT408520B (en) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Pharmaceutical formulations
CH686761A5 (en) * 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
FR2736550B1 (en) * 1995-07-14 1998-07-24 Sandoz Sa PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID DISPERSION COMPRISING A MACROLIDE AND A VEHICLE
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
JPH09278653A (en) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd Retinal disease-treating preparation
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
DE69907418T2 (en) * 1998-02-23 2003-11-13 Fujisawa Pharmaceutical Co., Ltd. USE OF MACROLIDES FOR TREATING GLAUCOMA
DE69900207T2 (en) * 1998-07-14 2001-11-22 Alcon Laboratories, Inc. USE OF 11- (3-DIMETHYLAMINOPROPYLIDES) -6.11-DIHYDRODIBENCE [B, E] OXEPIN-2-ACETIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT, NEDULATION, NEDULATION, NEDULATION, NEDULATION, NEDERATION, NEDULATION, NEDICULATION, NEDERATION, NON-DENTALIZATION
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
EP1140134A1 (en) * 1998-12-24 2001-10-10 R-Tech Ueno, Ltd. Agent for treating visual cell function disorder
EP1173177B2 (en) * 1999-04-30 2014-03-05 Sucampo AG Use of macrolide compounds for the treatment of dry eye
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
DK1319008T3 (en) 2000-09-19 2009-02-09 Wyeth Corp Water-soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US6534693B2 (en) 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
MXPA04001524A (en) 2001-08-22 2004-05-31 Wyeth Corp Rapamycin 29-enols.
JP2005511633A (en) * 2001-11-19 2005-04-28 ノバルティス アクチエンゲゼルシャフト Use of ascomycin for the treatment of blepharitis
EA008379B1 (en) 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Phosphorus-containing compounds & uses thereof
JP4265888B2 (en) * 2002-06-12 2009-05-20 株式会社リコー Image forming apparatus
ATE385795T1 (en) 2002-07-30 2008-03-15 Wyeth Corp PARENTERAL FORMULATIONS CONTAINING A RAPAMYCIN HYDROXYESTER
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
EP1539157B1 (en) * 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin for use in inhibiting or preventing choroidal neovascularization
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AR042938A1 (en) * 2003-02-06 2005-07-06 Wyeth Corp USE OF CCI-779 IN THE TREATMENT OF HEPATIC FIBROSIS
UA83484C2 (en) * 2003-03-05 2008-07-25 Уайт Method for treating breast cancer using combination of rapamycin derivative and aromatase inhibitor, pharmaceutical composition
DK1615640T3 (en) * 2003-04-22 2007-03-12 Wyeth Corp Antineoplastic Compositions
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US20060257450A1 (en) * 2005-03-21 2006-11-16 Sreenivasu Mudumba Drug delivery systems for treatment of diseases or conditions
BRPI0608152A2 (en) * 2005-02-09 2009-11-10 Macusight Inc eye care formulations
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP1890652B1 (en) 2005-05-13 2017-08-02 Akkolens International B.V. Intra-ocular artificial lens for iris-driven accommodation
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
US20070071754A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Method to ameliorate inflammation
JP5709354B2 (en) 2005-11-14 2015-04-30 アリアド・ファーマシューティカルズ・インコーポレイテッド Treatment of cancer patients with mTOR inhibitors
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
WO2007112052A2 (en) * 2006-03-23 2007-10-04 Macusight, Inc. Formulations and methods for vascular permeability-related diseases or conditions
RU2010104916A (en) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) METHOD FOR PREVENTION AND TREATMENT OF AGE DISEASES
WO2008033956A2 (en) 2006-09-13 2008-03-20 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2197461B1 (en) 2007-10-08 2018-02-21 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
AU2008329876A1 (en) * 2007-11-27 2009-06-04 Alcon Research, Ltd. Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate
JP2012504654A (en) * 2008-10-03 2012-02-23 エリクシアー メディカル コーポレイション Polycyclic lactone compound and method of using the same
KR20130128018A (en) * 2009-04-10 2013-11-25 하이얀 치 Novel anti-aging agents and methods to identify them
ES2537385T3 (en) * 2009-06-09 2015-06-08 Aurinia Pharmaceuticals Inc. Topical supply systems for ophthalmic use
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
US20140255355A1 (en) * 2013-03-07 2014-09-11 Stemnion, Inc. Methods for treating blepharitis
US11400080B2 (en) 2016-05-25 2022-08-02 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
US10668011B2 (en) 2016-06-30 2020-06-02 Durect Corporation Depot formulations
EP3576736A4 (en) 2017-02-10 2020-08-26 Torcept Therapeutics Inc. Rapamycin analog
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CA3067332A1 (en) 2017-06-16 2018-12-20 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
KR20220122612A (en) 2019-12-26 2022-09-02 산텐 세이야꾸 가부시키가이샤 Aqueous suspension composition containing sirolimus or its salt

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
BE877700A (en) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison PHARMACEUTICAL COMPOSITIONS BASED ON RAPAMYCIN FOR THE TREATMENT OF CARCINOGENIC TUMORS
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
IE66485B1 (en) * 1989-07-05 1996-01-10 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990048077A (en) * 1997-12-08 1999-07-05 전원중 Manufacturing method of artificial marble molding

Also Published As

Publication number Publication date
AU653415B2 (en) 1994-09-29
AU2035092A (en) 1993-01-28
DK0532862T3 (en) 1996-02-19
JP2568962B2 (en) 1997-01-08
IL102414A (en) 1996-08-04
CA2074641C (en) 1999-05-04
SK230792A3 (en) 1996-05-08
JPH05194212A (en) 1993-08-03
NZ243679A (en) 1997-06-24
IE922430A1 (en) 1993-01-27
IL102414A0 (en) 1993-01-14
ATE133336T1 (en) 1996-02-15
HU211218B (en) 1995-11-28
SK280511B6 (en) 2000-03-13
RU2048812C1 (en) 1995-11-27
CZ285660B6 (en) 1999-10-13
ES2083030T3 (en) 1996-04-01
CA2074641A1 (en) 1993-01-26
MX9204381A (en) 1993-02-01
CZ230792A3 (en) 1993-02-17
EP0532862A1 (en) 1993-03-24
EP0532862B1 (en) 1996-01-24
DE69207847T2 (en) 1996-05-30
DE69207847D1 (en) 1996-03-07
HU9202448D0 (en) 1992-10-28
HUT63763A (en) 1993-10-28
ZA924953B (en) 1993-04-28
US5387589A (en) 1995-02-07
KR100216768B1 (en) 1999-09-01
HK1005705A1 (en) 1999-01-22

Similar Documents

Publication Publication Date Title
KR930001913A (en) Eye Treatment
KR950016738A (en) How to suppress Alzheimer&#39;s disease
DK1514548T3 (en) Topical ophthalmic fluprostenol preparation for the treatment of glaucoma and ocular hypertension
KR950013511A (en) Incontinence Treatment
FI902258A0 (en) Process for the preparation of pharmacologically active 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2 alkyl esters
KR960701033A (en) COMPOUNDS HAVING BOTH POTENT CALCIUM ANTAGONIST AND ANTIOXIDANT ACTIVITY AND USE THERE OF AS CYTOPROTECTIVE AGENTS
ES2105333T3 (en) COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA.
KR940005270A (en) Benzothiophene Helps Prevent Bone Loss
KR970704452A (en) Topical ophthalmic formulations containing doxepin derivatives for the treatment of allergic eye diseases.
KR950016745A (en) Method of treating physiological symptoms and composition for same
KR950010888A (en) How to inhibit smooth muscle cell proliferation and restenosis
DK0735868T3 (en) Use of non-steroidal cyclooxygenase inhibitors for the manufacture of a medicament for the treatment of elevated intracellular
KR920012113A (en) How to Use Peptide Derivatives
KR950010892A (en) How to suppress uterine fibrosis
ATE15596T1 (en) PHARMACEUTICAL AGENT.
DK1110554T3 (en) Medications for the treatment of eye diseases
KR950016723A (en) How to suppress autoimmune diseases
KR940005274A (en) Sjoegren Syndrome Treatment
KR950016727A (en) How to increase thrombomodulin expression
KR950010889A (en) How to inhibit angiogenesis and angiogenic diseases
KR950016760A (en) Hemorrhoids Treatment
KR910004191A (en) Renal disease treatment
DK1187611T3 (en) Ophthalmic histamine-containing compositions and their use
KR900701259A (en) Polyvalent anti-inflammatory
KR910019623A (en) Treatment of Ocular Hypertension with Synergistic Combination

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040524

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee